Antihypertensive treatment of acute cerebral hemorrhage

Antihypertensive Treatment of Acute Cerebral Hemorrhage (ATACH) investigators, Adnan I Qureshi, Nauman Tariq, Afskin A Divani, Jill Novitzke, Haitham H Hussein, Yuko Y Palesch, Renee' Martin, Catherine Dillon, Jawad F Kirmani, Mustapha A Ezzeddine, Ibrahim Mohammad, M Fareed K Suri, Pansy Harris-Lane, Jose I Suarez, Eliahu Feen, Warren Selman, Christopher Murphy, Stephan A Mayer, Augusto Parra, Kiwon Lee, Noeleen Ostapkovich, Nikolaos I H Papamitsakis, Spozhmy Panezai, Chinekwu Anyanwu, John Terry, Kelly Dickerson, Joshua Goldstein, Lauren Wendell, Yousef M Mohammad, Hoda Jradi, Salvador Cruz-Flores, Eve Holzemer, Gene Sung, Vangie Thomson, As'ad Ehtisham, Betty Brown, William R Clarke, Steven Greenberg, Leslie Ain McClure, Emmy R Miller, J Paul Muizelaar, Howard Yonas, Antihypertensive Treatment of Acute Cerebral Hemorrhage (ATACH) investigators, Adnan I Qureshi, Nauman Tariq, Afskin A Divani, Jill Novitzke, Haitham H Hussein, Yuko Y Palesch, Renee' Martin, Catherine Dillon, Jawad F Kirmani, Mustapha A Ezzeddine, Ibrahim Mohammad, M Fareed K Suri, Pansy Harris-Lane, Jose I Suarez, Eliahu Feen, Warren Selman, Christopher Murphy, Stephan A Mayer, Augusto Parra, Kiwon Lee, Noeleen Ostapkovich, Nikolaos I H Papamitsakis, Spozhmy Panezai, Chinekwu Anyanwu, John Terry, Kelly Dickerson, Joshua Goldstein, Lauren Wendell, Yousef M Mohammad, Hoda Jradi, Salvador Cruz-Flores, Eve Holzemer, Gene Sung, Vangie Thomson, As'ad Ehtisham, Betty Brown, William R Clarke, Steven Greenberg, Leslie Ain McClure, Emmy R Miller, J Paul Muizelaar, Howard Yonas

Abstract

Objective: To determine the feasibility and acute (i.e., within 72 hrs) safety of three levels of systolic blood pressure reduction in subjects with supratentorial intracerebral hemorrhage treated within 6 hrs after symptom onset.

Design: A traditional phase I, dose-escalation, multicenter prospective study.

Settings: Emergency departments and intensive care units.

Patients: Patients with intracerebral hemorrhage with elevated systolic blood pressure > or = 170 mm Hg who present to the emergency department within 6 hrs of symptom onset.

Intervention: Intravenous nicardipine to reduce systolic blood pressure to a target of: (1) 170 to 200 mm Hg in the first cohort of patients; (2) 140 to 170 mm Hg in the second cohort; and (3) 110 to 140 mm Hg in the third cohort.

Measurements and main results: Primary outcomes of interest were: (1) treatment feasibility (achieving and maintaining the systolic blood pressure goals for 18-24 hrs); (2) neurologic deterioration within 24 hrs; and (3) serious adverse events within 72 hrs. Safety stopping rules based on neurologic deterioration and serious adverse events were prespecified and approved by an NIH-appointed Data and Safety Monitoring Board, which provided oversight on subject safety. Each subject was followed-up for 3 months to preliminarily assess mortality and the clinical outcomes. A total of 18, 20, and 22 patients were enrolled in the respective three tiers of systolic blood pressure treatment goals. Overall, 9 of 60 patients had treatment failures (all in the last tier). A total of seven subjects with neurologic deterioration were observed: one (6%), two (10%), and four (18%) in tier one, two, and three, respectively. Serious adverse events were observed in one subject (5%) in tier two and in three subjects (14%) in tier three. However, the safety stopping rule was not activated in any of the tiers. Three (17%), two (10%), and five (23%) subjects in tiers one, two, and three, respectively, died within 3 months.

Conclusions: The observed proportions of neurologic deterioration and serious adverse events were below the prespecified safety thresholds, and the 3-month mortality rate was lower than expected in all systolic blood pressure tiers. The results form the basis of a larger randomized trial addressing the efficacy of systolic blood pressure reduction in patients with intracerebral hemorrhage.

Conflict of interest statement

The authors have not disclosed any potential conflicts of interest.

Figures

Figure 1
Figure 1
Box plot of systolic blood pressure (SBP) recordings over a 24-hr period in each treatment group.

References

    1. Qureshi AI. Acute hypertensive response in patients with stroke: pathophysiology and management. Circulation. 2008;118:176–187.
    1. Qureshi AI, Suri MF, Nasar A, et al. Changes in cost and outcome among US patients with stroke hospitalized in 1990 to 1991 and those hospitalized in 2000 to 2001. Stroke. 2007;38:2180–2184.
    1. Wallace JD, Levy LL. Blood pressure after stroke. JAMA. 1981;246:2177–2180.
    1. Broderick JP, Brott TG, Tomsick T, et al. Ultra-early evaluation of intracerebral hemorrhage. J Neurosurg. 1990;72:195–199.
    1. Chen ST, Chen SD, Hsu CY, et al. Progression of hypertensive intracerebral hemorrhage. Neurology. 1989;39:1509–1514.
    1. Dandapani BK, Suzuki S, Kelley RE, et al. Relation between blood pressure and outcome in intracerebral hemorrhage. Stroke. 1995;26:21–24.
    1. Vemmos KN, Tsivgoulis G, Spengos K, et al. Association between 24-h blood pressure monitoring variables and brain oedema in patients with hyperacute stroke. J Hypertens. 2003;21:2167–2173. [see comment]
    1. Broderick JP, Diringer MN, Hill MD, et al. Determinants of intracerebral hemorrhage growth: an exploratory analysis. Stroke. 2007;38:1072–1075.
    1. Jauch EC, Lindsell CJ, Adeoye O, et al. Lack of evidence for an association between hemodynamic variables and hematoma growth in spontaneous intracerebral hemorrhage. Stroke. 2006;37:2061–2065.
    1. Qureshi AI, Tuhrim S, Broderick JP, et al. Spontaneous intracerebral hemorrhage. N Engl J Med. 2001;344:1450–1460.
    1. Qureshi AI, Mohammad YM, Yahia AM, et al. A prospective multicenter study to evaluate the feasibility and safety of aggressive antihypertensive treatment in patients with acute intracerebral hemorrhage. J Intensive Care Med. 2005;20:34–42.
    1. Kim-Han JS, Kopp SJ, Dugan LL, et al. Perihematomal mitochondrial dysfunction after intracerebral hemorrhage. Stroke. 2006;37:2457–2462.
    1. Powers WJ, Zazulia AR, Videen TO, et al. Autoregulation of cerebral blood flow surrounding acute (6 to 22 hours) intracerebral hemorrhage. Neurology. 2001;57:18–24.
    1. Broderick J, Connolly S, Feldmann E, et al. Guidelines for the management of spontaneous intracerebral hemorrhage in adults: 2007 update: a guideline from the American Heart Association/American Stroke Association Stroke Council, High Blood Pressure Research Council, and the Quality of Care and Outcomes in Research Interdisciplinary Working Group Stroke. J Cerebral Circ. 2007;38:2001–2023.
    1. Steiner T, Kaste M, Forsting M, et al. Recommendations for the management of intracranial haemorrhage—part I: Spontaneous intracerebral haemorrhage. The European Stroke Initiative Writing Committee and the Writing Committee for the EUSI Executive Committee. Cerebrovasc Dis. 2006;22:294–316.
    1. Qureshi AI. Antihypertensive Treatment of Acute Cerebral Hemorrhage (ATACH): Rationale and design. Neurocritical Care. 2007;6:56–66.
    1. Qureshi AI, Harris-Lane P, Kirmani JF, et al. Treatment of acute hypertension in patients with intracerebral hemorrhage using American Heart Association guidelines. Crit Care Med. 2006;34:1975–1980.
    1. Qureshi AI, Hutson AD, Harbaugh RE, et al. Methods and design considerations for randomized clinical trials evaluating surgical or endovascular treatments for cerebrovascular diseases. Neurosurgery. 2004;54:248–264. discussion 264–267.
    1. Qureshi AI, Harris-Lane P, Kirmani JF, et al. Intra-arterial reteplase and intravenous ab-ciximab in patients with acute ischemic stroke: an open-label, dose-ranging, phase I study. Neurosurgery. 2006;59:789–796. discussion 796–797.
    1. Cuzick J, Howell A, Forbes J. Early stopping of clinical trials. Breast Cancer Res. 2005;7:181–183.
    1. Wilhelmsen L. Role of the Data and Safety Monitoring Committee (DSMC) Stat Med. 2002;21:2823–2829.
    1. Asplund K. The role of the data safety and monitoring committee in stroke trials. Eur Neurol. 2003;49:115–119.
    1. Sydes MR, Spiegelhalter DJ, Altman DG, et al. Systematic qualitative review of the literature on data monitoring committees for randomized controlled trials. Clin Trials. 2004;1:60–79.
    1. Broderick J, Brott T, Tomsick T, et al. Management of intracerebral hemorrhage in a large metropolitan population. Neurosurgery. 1994;34:882–887. discussion 887.
    1. Broderick JP, Brott TG, Duldner JE, et al. Volume of intracerebral hemorrhage. A powerful and easy-to-use predictor of 30-day mortality. Stroke. 1993;24:987–993.
    1. Qureshi AI, Safdar K, Weil J, et al. Predictors of early deterioration and mortality in black Americans with spontaneous intracerebral hemorrhage. Stroke. 1995;26:1764–1767.
    1. Brott T, Broderick J, Kothari R, et al. Early hemorrhage growth in patients with intracerebral hemorrhage. Stroke. 1997;28:1–5.
    1. Valiente RA, de Miranda-Alves MA, Silva GS, et al. Clinical features associated with early hospital arrival after acute intracerebral hemorrhage: Challenges for new trials. Cere-brovasc Dis. 2008;26:404–408.
    1. Wallin JD, Fletcher E, Ram CV, et al. Intravenous nicardipine for the treatment of severe hypertension. A double-blind, placebo-controlled multicenter trial. Arch Intern Med. 1989;149:2662–2669.
    1. Halpern NA, Goldberg M, Neely C, et al. Post-operative hypertension: A multicenter, prospective, randomized comparison between intravenous nicardipine and sodium nitro-prusside. Crit Care Med. 1992;20:1637–1643.
    1. Efficacy and safety of intravenous nicardipine in the control of postoperative hypertension. IV Nicardipine Study Group. Chest. 1991;99:393–398.
    1. Flamm ES, Adams HP, Jr, Beck DW, et al. Dose-escalation study of intravenous nicardipine in patients with aneurysmal subarachnoid hemorrhage. J Neurosurg. 1988;68:393–400.
    1. Haley EC, Jr, Kassell NF, Torner JC, et al. A randomized trial of two doses of nicardipine in aneurysmal subarachnoid hemorrhage. A report of the Cooperative Aneurysm Study. J Neurosurg. 1994;80:788–796.
    1. Nishiyama T, Yokoyama T, Matsukawa T, et al. Continuous nicardipine infusion to control blood pressure after evacuation of acute cerebral hemorrhage. Can J Anaesthesia. 2000;47:1196–1201.
    1. Anderson CS, Huang Y, Wang G, et al. Intensive blood pressure reduction in acute cerebral haemorrhage trial (INTERACT): A pilot randomised trial. Lancet Neurol. 2008;7:391–399.
    1. Sorimachi T, Fujii Y, Morita K, et al. Rapid administration of antifibrinolytics and strict blood pressure control for intracerebral hemorrhage. Neurosurgery. 2005;57:837–844.
    1. Ohwaki K, Yano E, Nagashima H, et al. Blood pressure management in acute intracerebral hemorrhage: relationship between elevated blood pressure and hematoma enlargement. Stroke. 2004;35:1364–1367.
    1. Broderick JP, Adams HP, Jr, Barsan W, et al. Guidelines for the management of spontaneous intracerebral hemorrhage: A statement for healthcare professionals from a special writing group of the Stroke Council, American Heart Association. Stroke. 1999;30:905–915.
    1. Qureshi AI, Wilson DA, Hanley DF, et al. Pharmacologic reduction of mean arterial pressure does not adversely affect regional cerebral blood flow and intracranial pressure in experimental intracerebral hemorrhage. Crit Care Med. 1999;27:965–971.
    1. Mayer SA, Brun NC, Begtrup K, et al. Recombinant activated factor VII for acute intracerebral hemorrhage. N Engl J Med. 2005;352:777–785.
    1. Sprague S, Leece P, Bhandari M, et al. Limiting loss to follow-up in a multicenter randomized trial in orthopedic surgery. Control Clin Trials. 2003;24:719–725.

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren